Article
Gastroenterology & Hepatology
Aldo J. Montano-Loza, Vincenzo Ronca, Maryam Ebadi, Bettina E. Hansen, Gideon Hirschfield, Saleh Elwir, Mohamad Alsaed, Piotr Milkiewicz, Maciej K. Janik, Hanns-Ulrich Marschall, Maria Antonella Burza, Cumali Efe, Ali Riza Caliskan, Murat Harputluoglu, Gokhan Kabacam, Debora Terrabuio, Fernanda de Quadros Onofrio, Nazia Selzner, Alan Bonder, Albert Pares, Laura Llovet, Murat Akyildiz, Cigdem Arikan, Michael P. Manns, Richard Taubert, Anna-Lena Weber, Thomas D. Schiano, Brandy Haydel, Piotr Czubkowski, Piotr Socha, Natalia Oldak, Nobuhisa Akamatsu, Atsushi Tanaka, Cynthia Levy, Eric F. Martin, Aparna Goel, Mai Sedki, Irena Jankowska, Toru Ikegami, Maria Rodriguez, Martina Sterneck, Christina Weiler-Normann, Christoph Schramm, Maria Francesca Donato, Ansgar Lohse, Raul J. Andrade, Vilas R. Patwardhan, Bart van Hoek, Maaike Biewenga, Andreas E. Kremer, Yoshihide Ueda, Mark Deneau, Mark Pedersen, Marlyn J. Mayo, Annarosa Floreani, Patrizia Burra, Maria Francesca Secchi, Benedetta Terziroli Beretta-Piccoli, Marco Sciveres, Giuseppe Maggiore, Syed-Mohammed Jafri, Dominique Debray, Muriel Girard, Florence Lacaille, Ellina Lytvyak, Andrew L. Mason, Michael Heneghan, Ye Htun Oo
Summary: Recurrence of autoimmune hepatitis (AIH) is common after liver transplantation, and it is associated with younger age at transplantation, the use of mycophenolate mofetil post-transplant, sex mismatch, and high pre-transplant IgG levels. Recurrent AIH is associated with impaired graft and overall survival. Better characterization, prevention, and treatment strategies are needed for the management of recurrent AIH.
JOURNAL OF HEPATOLOGY
(2022)
Article
Virology
Qing-Lei Zeng, Zu-Jiang Yu, Jun Lv, Hong-Xu Zhang, Bin Wang, Xiao-Ping Dong, Zhi-Min Chen, Guang-Lin Cui, Fanpu Ji
Summary: This study found that sofosbuvir-based therapy is safe and effective for pregnant women and infants with severe chronic hepatitis C. The data provided evidence to support the use of sofosbuvir-based therapy in similar situations in clinical practice.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Gastroenterology & Hepatology
Eleonora De Martin, Audrey Coilly, Olivier Chazouilleres, Olivier Roux, Jean-Marie Peron, Pauline Houssel-Debry, Florent Artru, Christine Silvain, Isabelle Ollivier-Hourmand, Christophe Duvoux, Alexandra Heurgue, Sandrine Barge, Nathalie Ganne-Carrie, Georges-Philippe Pageaux, Camille Besch, Marc Bourliere, Helene Fontaine, Victor de Ledinghen, Jerome Dumortier, Filomena Conti, Sylvie Radenne, Marilyne Debette-Gratien, Odile Goria, Francois Durand, Pascal Potier, Vincent Di Martino, Noemi Reboux, Philippe Ichai, Mylene Sebagh, Philippe Mathurin, Helene Agostini, Didier Samuel, Jean-Charles Duclos-Vallee
Summary: In patients with AS-AIH, INR at the initiation of corticosteroids and the evolution of INR and bilirubin are predictive of LT or death. The SURFASA score, created by combining these variables, can accurately identify non-responders who require urgent referral for LT. This scoring system should be validated in a prospective cohort study.
JOURNAL OF HEPATOLOGY
(2021)
Article
Infectious Diseases
Miguel Gorgolas Hernandez-Mora, Alfonso Cabello Ubeda, Laura Prieto-Perez, Felipe Villar Alvarez, Beatriz Alvarez Alvarez, Maria Jesus Rodriguez Nieto, Irene Carrillo Acosta, Itziar Fernandez Ormaechea, Aws Waleed Mohammed Al-Hayani, Pilar Carballosa, Silvia Calpena Martinez, Farah Ezzine, Marina Castellanos Gonzalez, Alba Naya, Marta Lopez Heras, Marcel Jose Rodriguez Guzman, Ana Cordero Guijarro, Antonio Broncano Lavado, Alicia Macias Valcayo, Marta Martin Garcia, Javier Becares Martinez, Ricardo Fernandez Roblas, Miguel Angel Piris Pinilla, Jose Fortes Alen, Olga Sanchez Pernaute, Fredeswinda Romero Bueno, Sarah Heili-Frades, German Peces-Barba Romero
Summary: Tocilizumab (TCZ) is well tolerated in patients with severe SARS-CoV-2 pneumonia (SSP), but has limited effect on cases with high oxygen support needs.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Pediatrics
David L. Goldman, Margaret L. Aldrich, Stefan H. F. Hagmann, Alasdair Bamford, Andres Camacho-Gonzalez, Giuseppe Lapadula, Philip Lee, Paolo Bonfanti, Christoph C. Carter, Yang Zhao, Laura Telep, Cheryl Pikora, Sarjita Naik, Neal Marshall, Ioannis Katsarolis, Moupali Das, Adam DeZure, Polly Desai, Huyen Cao, Anand P. Chokkalingam, Anu Osinusi, Diana M. Brainard, Ana Mendez-Echevarria
Summary: Among the 77 children treated with remdesivir for severe COVID-19, most recovered and the rate of serious adverse events was low. In the study, a small number of patients died, but Remdesivir was considered a safe and effective treatment that improved symptoms and reduced hospitalization time.
Article
Immunology
Richard M. Burwick, Sigal Yawetz, Kathryn E. Stephenson, Ai-Ris Y. Collier, Pritha Sen, Brian G. Blackburn, E. Milunka Kojic, Adi Hirshberg, Jose F. Suarez, Magdalena E. Sobieszczyk, Kristen M. Marks, Shawn Mazur, Cecilia Big, Oriol Manuel, Gregory Morlin, Suzanne J. Rose, Mariam Naqvi, Ilona T. Goldfarb, Adam DeZure, Laura Telep, Susanna K. Tan, Yang Zhao, Tom Hahambis, Jason Hindman, Anand P. Chokkalingam, Christoph Carter, Moupali Das, Anu O. Osinusi, Diana M. Brainard, Tilly A. Varughese, Olga Kovalenko, Matthew D. Sims, Samit Desai, Geeta Swamy, Jeanne S. Sheffield, Rebecca Zash, William R. Short
Summary: The study demonstrates high recovery rates and a low incidence of serious adverse events among 86 pregnant and postpartum women with severe COVID-19 who received compassionate use remdesivir.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Hussein A. AbdEl-maksoud, Mohamed G. Elharrif, Omnia Abd El-hamid, Saad M. Alsaab, Eman M. El-sorady
Summary: The study monitored iron, lipid, and liver profiles in hepatitis C patients before and during treatment with sofosbuvir antiviral drug. Results showed significant improvement in serum iron, cholesterol, and other parameters, while serum ferritin, transferrin, and other indicators increased significantly after treatment with sofosbuvir, indicating amelioration of disruption caused by hepatitis C virus infection.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)
Article
Gastroenterology & Hepatology
Naoto Fujiwara, Eric Trepo, Indu Raman, Quan-Zhen Li, Delphine Degre, Thierry Gustot, Christophe Moreno, Yujin Hoshida
Summary: The study identified a 6-plasma-protein panel as a surrogate for the 123-gene signature in severe alcoholic hepatitis patients. The composite score ps-MELD, combining plasma signature with MELD score, showed a strong association with short-term survival, outperforming existing clinical scores.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xia Yao, Shuai Gao, Jixin Wang, Zhangqiang Li, Jian Huang, Yan Wang, Zhifei Wang, Jiaofeng Chen, Xiao Fan, Weipeng Wang, Xueqin Jin, Xiaojing Pan, Yong Yu, Armando Lagrutta, Nieng Yan
Summary: The study reveals the molecular basis for the physical and pharmacodynamic interaction of sofosbuvir and amiodarone on the scaffold of Cav channels.
Article
Gastroenterology & Hepatology
Giacomo Germani, Philippe Mathurin, Michael R. Lucey, James Trotter
Summary: In patients with severe acute alcohol-related hepatitis, liver transplantation is the only effective therapy, but there is still limited access to transplantation due to emphasis on pre-transplant abstinence and societal stigma. Therefore, there is a growing need for multicenter studies to improve selection practices and interventions for alcohol use disorder after transplantation.
JOURNAL OF HEPATOLOGY
(2023)
Article
Surgery
Giacomo Germani, Debora Angrisani, Giovanni Addolorato, Manuela Merli, Chiara Mazzarelli, Claudia Tarli, Barbara Lattanzi, Adelaide Panariello, Paola Prandoni, Lucia Craxi, Giovanni Forza, Alessandra Feltrin, Andrea Ronzan, Paolo Feltracco, Antonio Grieco, Salvatore Agnes, Antonio Gasbarrini, Massimo Rossi, Luciano De Carlis, D'Amico Francesco, Umberto Cillo, Luca S. Belli, Patrizia Burra
Summary: This study assessed the outcomes of early liver transplantation (eLT) in patients with severe alcoholic hepatitis (sAH) and found that eLT significantly improved survival in non-responders to medical therapy, when a strict selection process was applied.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Review
Gastroenterology & Hepatology
Lucija Virovic-Jukic, Dominik Ljubas, Sanja Stojsavljevic-Shapeski, Neven Ljubicic, Tajana Filipec Kanizaj, Ivana Mikolasevic, Ivica Grgurevic
Summary: Severe alcoholic hepatitis has limited treatment options and poor outcomes with current supportive medical care and corticosteroids. While new treatment options like granulocyte colony-stimulating factor and stem cell transplantation are being explored, evidence for their efficacy remains scarce and further research is needed. Insights into the pathogenesis of AH and liver regeneration processes are crucial for the development of new treatment options, but high-quality studies and reliable experimental models are lacking.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Surgery
Aranzazu Caballero-Marcos, Mario Romero-Cristobal, Marta Puerto, Ainhoa Fernandez-Yunquera, Lucia Dieguez, Cristina Navarrete, Ana Clemente, Fernando Diaz-Fontenla, Pilar Catalan, Diego Rincon, Jose-Angel Lopez-Baena, Rafael Banares Canizares, Magdalena Salcedo
Summary: Hepatitis C virus (HCV) may increase the risk of cardiovascular disease after liver transplantation, but HCV eradication can potentially reduce inflammatory and endothelial activation levels in patients, leading to the restoration of endothelial function.
TRANSPLANT INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Catrina M. Loucks, Jennifer J. Lin, Jessica N. Trueman, Britt Drogemoller, Galen E. B. Wright, Wan-Chun Chang, Kathy H. Li, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Pam Crotty, Richard B. Kim, Bandar Al-Judaibi, Ute Schwarz, Alnoor Ramji, Jeanette F. Farivar, Edward Tam, Lori Lee Walston, Colin J. D. Ross, Bruce C. Carleton
Summary: This study demonstrates that patient-specific genetic factors can be used as a tool to identify patients at higher risk of treatment failure, allowing for these patients to receive effective therapy sooner.
LIVER INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, Ching-Chu Lo, Wei-Wen Su, Kuo-Chih Tseng, Chun-Jen Liu, Chia-Sheng Huang, Ke-Jhang Huang, Sheng-Shun Yang, Cheng-Yuan Peng, Ming-Chang Tsai, Wei-Yu Kao, Chi-Yang Chang, Yu-Lueng Shih, Yu-Jen Fang, Chi-Yi Chen, Pei-Lun Lee, Jow-Jyh Huang, Pei-Yuan Su, Chi-Wei Tseng, Chien-Ching Hung, Chung-Hsin Chang, Yi-Jie Huang, Hsueh-Chou Lai, Chun-Chao Chang, Fu-Jen Lee, Tsai-Yuan Hsieh, Jia-Horng Kao
Summary: The study showed that SOF/VEL for 12 weeks is effective and well-tolerated in chronic HCV-infected patients with compensated liver disease in Taiwan, with SVR12 rates ranging from 95.6% to 99.3%. Adverse events were generally mild, with only a small percentage of patients discontinuing treatment due to AEs.
HEPATOLOGY INTERNATIONAL
(2021)
Editorial Material
Gastroenterology & Hepatology
Sergio Rodriguez-Tajes, Sabela Lens, Xavier Forns
JOURNAL OF VIRAL HEPATITIS
(2021)
Article
Gastroenterology & Hepatology
Teresa Broquetas, Paula Herruzo-Pino, Zoe Marino, Dolores Naranjo, Mercedes Vergara, Rosa M. Morillas, Xavier Forns, Jose A. Carrion
Summary: Cirrhosis is present in more than half of HCV-cACLD patients 3 years after SVR, despite the normalization of liver function parameters, serological non-invasive tests, and TE values. The low diagnostic accuracy of non-invasive methods after SVR highlights the necessity of long-term surveillance.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Xavier Forns, Joan Colom, Montse Garcia-Retortillo, Joan Carles Quer, Sabela Lens, Elisa Martro, Raquel Dominguez-Hernandez, Miguel Angel Casado, Maria Buti
Summary: This study aimed to evaluate and compare different strategies for HCV testing, linkage to care, and treatment in Catalonia. The results showed that implementing a Hepatitis C Point-of-care (POC) test and treat strategy significantly increased treatment access, cure rates, and reduced loss to follow-up for HCV patients.
JOURNAL OF VIRAL HEPATITIS
(2022)
Editorial Material
Medicine, General & Internal
Joachim Lupberger, Thomas F. Baumert
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Zakaria Boulahtouf, Alessia Virzi, Thomas F. Baumert, Eloi R. Verrier, Joachim Lupberger
Summary: Chronic viral hepatitis is a major cause of liver disease and hepatocellular carcinoma. Despite being caused by different viruses, hepatitis B, C, and D have striking similarities in pathological impact. The advancements in omics and bioinformatics have revealed the important role of signaling networks in viral pathogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Virology
Andrea Magri, James M. Harris, Valentina D'Arienzo, Rosalba Minisini, Frank Juhling, Peter A. C. Wing, Rachele Rapetti, Monica Leutner, Barbara Testoni, Thomas F. Baumert, Fabien Zoulim, Peter Balfe, Mario Pirisi, Jane A. McKeating
Summary: Chronic hepatitis B virus (HBV) infection is a global health problem that is characterized by interactions between the virus and the host immune system, leading to a spectrum of liver disease. The study investigates the contribution of HBV genomes, including episomal covalently closed circular DNA (cccDNA) and chromosomal integrants, to viral transcripts in chronic hepatitis B (CHB). The results demonstrate that cccDNA-derived transcripts are associated with liver inflammation markers, while integrant-derived transcripts are significantly associated with increasing age but not with inflammatory status.
Review
Medicine, General & Internal
Valerio Taverniti, Gaetan Ligat, Yannick Debing, Dieudonne Buh Kum, Thomas F. Baumert, Eloi R. Verrier
Summary: Despite the availability of a preventive vaccine, over 250 million people are still affected by chronic hepatitis B virus (HBV) infection, which is a major cause of liver disease and hepatocellular carcinoma. The core protein of HBV plays a crucial role in the virus's life cycle and represents a promising target for the development of new antiviral therapies. Capsid assembly modulators (CAM) have shown potent antiviral activity in cell-based and in vivo models, and several CAMs are currently being developed for clinical use.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Monica Pons, Jesus Rivera-Esteban, Ramiro Manzano, Juan Banares, Maria Bermudez, Victor Vargas, Maria Teresa Salcedo-Allende, Lluis Castells, Salvador Augustin, Beatriz Minguez, Juan M. Pericas
Summary: In a Spanish cohort of NAFLD patients, HCC was rare in non-cirrhotic patients. Non-invasive tests (NITs) may have a significant role in predicting HCC.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jordan J. Feld, Xavier Forns, Douglas E. Dylla, Hiromitsu Kumada, Victor de Ledinghen, Lai Wei, Robert S. Brown, Robert Flisiak, Pietro Lampertico, Dominique Thabut, Mark Bondin, Fernando Tatsch, Margaret Burroughs, John Marcinak, Zhenzhen Zhang, Amanda Emmett, Ira M. Jacobson
Summary: This study examines the safety of the direct-acting antiviral (DAA) regimen glecaprevir/pibrentasvir (G/P) in patients with compensated cirrhosis. The results show that G/P is well tolerated and safe for use in patients with compensated cirrhosis, including those with markers of advanced liver disease.
JOURNAL OF VIRAL HEPATITIS
(2022)
Review
Gastroenterology & Hepatology
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Cell Biology
Zeina Nehme, Natascha Roehlen, Punita Dhawan, Thomas F. F. Baumert
Summary: Tight junctions (TJs) are intercellular protein complexes that control paracellular permeability and cell polarity, and recent studies have shown their functional role beyond these classic functions. TJ proteins play crucial roles in cancer pathogenesis by modulating key signaling pathways that regulate cell proliferation, migration, and differentiation, as well as promoting stem cell phenotypes in cancer cells. Additionally, TJ proteins have been used as therapeutic targets and prognostic markers in preclinical and clinical studies. This review summarizes the functional role of TJ proteins in cancer biology and their potential for novel cancer prevention and treatment strategies.
Editorial Material
Gastroenterology & Hepatology
Nikolaus Jilg, Thomas F. Baumert
Article
Gastroenterology & Hepatology
Dieudonne Buh Kum, Hannah Vanrusselt, Abel Acosta Sanchez, Valerio Taverniti, Eloi R. Verrier, Thomas F. Baumert, Cheng Liu, Jerome Deval, Nikky Corthout, Sebastian Munck, Leonid Beigelman, Lawrence M. Blatt, Julian A. Symons, Pierre Raboisson, Andreas Jekle, Sandrine Vendeville, Yannick Debing
Summary: This study uncovers a novel mechanism of action for CAM-As in the treatment of chronic hepatitis B, where HBc aggregation induces cell death, leading to hepatocyte proliferation and loss of covalently closed circular DNA or its equivalent, possibly assisted by an induced innate immune response.
Article
Endocrinology & Metabolism
Zoe Marino, Cristina Molera-Busoms, Celia Badenas, Jesus Quintero-Bernabeu, Merce Torra, Xavier Forns, Rafael Artuch
Summary: Wilson disease is a complex disease with challenging diagnosis and long-term copper control. Exchangeable copper and its ratio have been suggested as useful biomarkers, and this study evaluated their performance in a cohort of WD patients. The results confirmed that REC is a useful marker for WD identification, with 71.4% of recent diagnosis patients having REC >= 18.5% and 95.1% of long-term treated WD patients having REC >= 14%. Exchangeable copper was also higher in WD patients and tended to be reduced in compliant patients. These biomarkers can complement the diagnosis and copper homeostasis monitoring in WD.
JOURNAL OF INHERITED METABOLIC DISEASE
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Alessia Virzi, Laura Heydmann, Sarah Durand, Emanuele Felli, Patrick Pessaux, Eloi Verrier, Catherine Schuster, Thomas Baumert, Joachim Lupberger
JOURNAL OF HEPATOLOGY
(2021)